What is ImmunityBio, Inc.'s R&D?

ImmunityBio, Inc. (IBRX) reported R&D of $35.22M in Q4 2024.

How has ImmunityBio, Inc.'s R&D changed year-over-year?

ImmunityBio, Inc.'s R&D decreased by 31.7% year-over-year, from $51.53M to $35.22M.

What is the long-term trend for ImmunityBio, Inc.'s R&D?

Over 3 years (2021 to 2024), ImmunityBio, Inc.'s R&D has grown at a -1.0% compound annual growth rate (CAGR), from $195.96M to $190.14M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

ImmunityBio, Inc. IBRX R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

Merck & Co.MRK

$12.59B+248%

Summit TherapeuticsSMMT

$132.62M+159%

Immunovant, Inc.IMVT

——

Kymera TherapeuticsKYMR

——

Protagonist TherapeuticsPTGX

——

Segments

By segment

See full

Reportable Segment$67.99M+41.0%

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: ImmunityBio, Inc.’s 10-K, filed March 3, 2025, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s R&D?: ImmunityBio, Inc. (IBRX) reported R&D of $35.22M in Q4 2024.
How has ImmunityBio, Inc.'s R&D changed year-over-year?: ImmunityBio, Inc.'s R&D decreased by 31.7% year-over-year, from $51.53M to $35.22M.
What is the long-term trend for ImmunityBio, Inc.'s R&D?: Over 3 years (2021 to 2024), ImmunityBio, Inc.'s R&D has grown at a -1.0% compound annual growth rate (CAGR), from $195.96M to $190.14M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.